Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer

Oncologist

Volumn 16, Issue 4, 2011, Pages 404-414

  Hernandez Aya, Leonel F ^a   Gonzalez Angulo, Ana M ^b  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ANTINEOPLASTIC AGENT; AZD 8055; BEVACIZUMAB; BKM 120; BYL 719; CAL 101; CAPECITABINE; CARBOPLATIN; EVEROLIMUS; EXEMESTANE; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MK 2206; NAVELBINE; PACLITAXEL; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; RIDAFOROLIMUS; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 147; XL 765;

ADVANCED CANCER; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE ACTIVATION; GENE MUTATION; HUMAN; INTESTINE PERFORATION; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; ONCOGENE; PIK3CA GENE; PRIORITY JOURNAL; PTEN GENE; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; ENZYME INHIBITORS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOPROTEINS; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 79955555659     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0402     Document Type: Article

References (108)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-3695.
3. Chang HW, Aoki M, Fruman D et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 1997;276: 1848-1850.
4. Hoeflich KP, O'Brien C, Boyd Z et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009;15:4649-4664.
5. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006;18:77-82.
6. Agarwal R, Carey M, Hennessy B et al. PI3K pathway-directed therapeutic strategies in cancer. Curr Opin Investig Drugs 2010;11:615-628.
7. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998;67:481-507.
8. Guillermet-Guibert J, Bjorklof K, Salpekar A et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream ofGprotein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A 2008;105:8292-8297.
9. Luo J, Cantley LC. The negative regulation of phosphoinositide 3-kinase signaling by p85 and its implication in cancer. Cell Cycle 2005;4:1309-1312.
10. Bellacosa A, Testa JR, Staal SP et al. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991; 254:274-277.
11. Wang DS, Ching TT, St Pyrek J et al. Biotinylated phosphatidylinositol 3,4,5-trisphosphate as affinity ligand. Anal Biochem 2000;280:301-307.
12. Hennessy BT, Smith DL, Ram PT et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
13. Tokunaga E, Oki E, Egashira A et al. Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008;8:27-36.
14. Katso R, Okkenhaug K, Ahmadi K et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001;17:615-675.
15. Inoki K, Li Y, Zhu T et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002;4:648-657.
16. Manning BD, Tee AR, Logsdon MN et al. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 2002;10:151-162.
17. Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 2002;4:658-665.
18. Li Y, Corradetti MN, Inoki K et al. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 2004;29:32-38.
19. Oshiro N, Takahashi R, Yoshino K et al. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 2007;282:20329-20339.
20. Wang L, Harris TE, Roth RA et al. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 2007;282:20036-20044.
21. Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 2009;36 Suppl 3:S3-S17.
22. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253-262.
23. Kim DH, Sabatini DM. Raptor and mTOR: subunits of a nutrient-sensitive complex. Curr Top Microbiol Immunol 2004;279:259-270.
24. Barbet NC, Schneider U, Helliwell SB et al. TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell 1996;7:25-42.
25. Brunn GJ, Hudson CC, Sekulic A et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997;277:99-101.
26. Gingras AC, Raught B, Sonenberg N. EIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999;68:913-963.
27. Dorrello NV, Peschiaroli A, Guardavaccaro D et al. S6K1-and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006;314:467-471.
28. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-484.
29. Browne GJ, Proud CG. A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol Cell Biol 2004;24:2986-2997.
30. Proud CG. MTORC1 signalling and mRNA translation. Biochem Soc Trans 2009;37:227-231.
31. Sarbassov DD, Ali SM, Kim DH et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296-1302.
32. Huang J, Dibble CC, Matsuzaki M et al. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 2008;28: 4104-4115.
33. Sarbassov DD, Guertin DA, Ali SM et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-1101.
34. Gulhati P, Cai Q, Li J et al. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res 2009;15:7207-7216.
35. Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-168.
36. Ozes ON, Akca H, Mayo LD et al. A phosphatidylinositol 3-kinase/Akt/ mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci U S A 2001;98:4640-4645.
37. Tremblay F, Brule S, Hee Um S et al. Identification of IRS-1 Ser-1101 asa target of S6K1 in utrient-and obesity-induced insulin resistance. Proc Natl Acad Sci U S A 2007;104:14056-14061.
38. O'Reilly KE, Rojo F, She QB et al. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66: 1500-1508.
39. Brugge J, Hung MC, Mills GB.Anew mutational AKTivation in the PI3K pathway. Cancer Cell 2007;12:104-107.
40. Krasilnikov MA. Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry (Mosc) 2000;65:59-67.
41. Bayascas JR, Leslie NR, Parsons R et al. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(_/_) mice. Curr Biol 2005;15:1839-1846.
42. Chen ML, Xu PZ, Peng XD et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten_/_ mice. Genes Dev 2006;20: 1569-1574.
43. Mills GB, Kohn E, Lu Y et al. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 2003;30:93-104.
44. Lopez-Knowles E, O'Toole SA, McNeil CM et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010;126:1121-1131.
45. Vasudevan KM, Barbie DA, Davies MA et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009;16:21-32.
46. Saal LH, Johansson P, Holm K et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad SciUSA 2007;104:7564-7569.
47. Nakamura N, Ramaswamy S, Vazquez F et al. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 2000;20:8969-8982.
48. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad SciUSA 2005; 102:802-807.
49. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-1947.
50. Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997;57:2124-2129.
51. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 2000; 1470:M21-M35.
52. Carnero A, Blanco-Aparicio C, RennerO et al. The PTEN/PI3K/AKT signaling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008;8:187-198.
53. Perren A, Weng LP, Boag AH et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999;155:1253-1260.
54. Bose S, Wang SI, Terry MB et al. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 1998; 17:123-127.
55. Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTENdeficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314-10319.
56. Shi Y, Gera J, Hu L et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002;62:5027-5034.
57. Steelman LS, Navolanic PM, Sokolosky ML et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 2008;27:4086-4095.
58. Bose S, Chandran S, Mirocha JM et al. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 2006;19:238-245.
59. Lee JS, Kim HS, Kim YB et al. Reduced PTEN expression is associated with poor outcome and angiogenesis in invasive ductal carcinoma of the breast. Appl Immunohistochem Mol Morphol 2004;12:205-210.
60. Bachman KE, Argani P, Samuels Y et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3: 772-775.
61. Saal LH, Holm K, Maurer M et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-2559.
62. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
63. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008;68:6084-6091.
64. Li SY, Rong M, Grieu F et al. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006;96:91-95.
65. Maruyama N, Miyoshi Y, Taguchi T et al. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007;13:408-414.
66. Slagsvold T, Marchese A, Brech A et al. CISK attenuates degradation of the chemokine receptor CXCR4 via the ubiquitin ligase AIP4. EMBO J 2006;25:3738-3749.
67. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3_ kinase/AKT pathways. Oncogene 2005;24:7443-7454.
68. Thant AA, Nawa A, Kikkawa F et al. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin Exp Metastasis 2000;18:423-428.
69. Arboleda MJ, Lyons JF, Kabbinavar FF et al. Overexpression of AKT2/ protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 2003;63:196-206.
70. Maroulakou IG, Oemler W, Naber SP et al. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 2007;67:167-177.
71. Irie HY, Pearline RV, Grueneberg D et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 2005;171:1023-1034.
72. Yoeli-Lerner M, Yiu GK, Rabinovitz I et al. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 2005;20:539-550.
73. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007; 26:1338-1345.
74. Bellacosa A, de Feo D, Godwin AK et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64: 280-285.
75. Nakatani K, Thompson DA, Barthel A et al. Up-regulation of Akt3 in es-trogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21528-21532.
76. Dillon RL, Muller WJ. Distinct biological roles for the akt family in mammary tumor progression. Cancer Res 2010;70:4260-4264.
77. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
78. Loi S, Haibe-Kains B, Majjaj S et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 2010;107: 10208-10213.
79. Cizkova M, Cizeron-Clairac G, Vacher S et al. Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway. PLoS One 2010;5: e15647.
80. Cui X, Schiff R, Arpino G et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005;23:7721-7735.
81. Bardou VJ, Arpino G, Elledge RM et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-1979.
82. Arpino G, Wiechmann L, Osborne CK et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008;29:217-233.
83. Lee AV, Guler BL, Sun X et al. Oestrogen receptor is a critical component required for insulin-like growth factor (IGF)-mediated signalling and growth in MCF-7 cells. Eur J Cancer 2000;36 Suppl 4:109-110.
84. Martin MB, Franke TF, Stoica GE et al. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 2000;141:4503-4511.
85. Kato S, Endoh H, Masuhiro Y et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-1494.
86. Razandi M, Pedram A, Park ST et al. Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 2003;278:2701-2712.
87. De Laurentiis M, Arpino G, Massarelli E et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:4741-4748.
88. Arpino G, Green SJ, Allred DC et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004; 10:5670-5676.
89. Martin LA, Head JE, Pancholi S et al. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol Cancer Ther 2007;6:2458-2467.
90. deGraffenried LA, Friedrichs WE, Russell DH et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004;10:8059-8067.
91. Creighton CJ, Fu X, Hennessy BT et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogenreceptor (ER) levels and activity in ER_breast cancer. Breast Cancer Res 2010;12:R40.
92. Rexer BN, Ghosh R, Arteaga CL. Inhibition of PI3K and MEK: it is all about combinations and biomarkers. Clin Cancer Res 2009;15:4518-4520.
93. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-127.
94. O'Brien NA, Browne BC, Chow L et al. Activated phosphoinositide 3-kinase/ AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010;9:1489-1502.
95. Junttila TT, Akita RW, Parsons K et al. Ligand-independent HER2/ HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009;15:429-440.
96. Esteva FJ, Guo H, Zhang S et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010;177:1647-1656.
97. Marone R, Cmiljanovic V, Giese B et al. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008;1784:159-185.
98. Knight ZA, Gonzalez B, Feldman ME et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006; 125:733-747.
99. Yap TA, Garrett MD, Walton MI et al. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008;8: 393-412.
100. Luo Y, Shoemaker AR, Liu X et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005;4: 977-986.
101. Zhao Z, Leister WH, Robinson RG et al. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg Med Chem Lett 2005;15:905-909.
102. Lindsley CW. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. Curr Top Med Chem 2010;10:458-477.
103. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28:721-726.
104. Choi J, Chen J, Schreiber SL et al. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996;273:239-242.
105. Kuo CJ, Chung J, Fiorentino DF et al. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992;358:70-73.
106. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009;27:2278-2287.
107. Leary A, Dowsett M. Combination therapy with aromatase inhibitors: the next era of breast cancer treatment? Br J Cancer 2006;95:661-666.
108. Sun SY, Rosenberg LM, Wang X et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-7058.